A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation

Bone Marrow Transplantation

Volumn 23, Issue 7, 1999, Pages 705-709

  Stocchi, R ^a,d   Szydlo, R ^a   Craddock, C ^a   Kanfer, E ^a   Apperley, J F ^a   Goldman, J M ^a   Ward, K N ^b,c  

^a Experimental Haematology   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Cytomegalovirus; Ganciclovir; Pre emptive; Prophylactic; Volunteer unrelated donor bone marrow transplant

Indexed keywords

ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; WHOLE BODY RADIATION;

EID: 0032891224     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701629     Document Type: Article

References (30)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic bone marrow transplantation: a review of 10 years' experience. Rev Infect Dis 1982; 4: 1119-1132.
3. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplant. Ann Intern Med 1988; 109: 783-788.
4. Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high dose intravenous immunoglobulin. Ann Intern Med 1988; 109: 777-782.
5. Schmidt GM, Kovacs A, Zaia JA et al. Ganciclovir/ immunoglobulin combination therapy for the treatment of human CMV-associated interstitial pneumonitis in bone marrow allograft recipients. Transplantation 1988; 46: 905-907.
6. Goodrich JM, Mon M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
7. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
8. Goodrich JM, Bowden AR, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
9. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic marrow transplants. Ann Intern Med 1993; 118: 179-184.
10. Ward KN, Roberts IAG, van Rhee F. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital. Bone Marrow Transplant 1994; 13: 230-231.
11. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
12. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. Ann Intern Med 1993; 119: 207-214.
13. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporin versus cyclosporin alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
14. Griffiths PD, Stirk PR, Ganczakowski M et al. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet 1984; 2: 1242-1245.
15. Ljungman P, Griffiths P. Definitions of CMV infection and disease. In: Plotkin ES, Michelson S (eds). Multidisciplinary Approach to Understanding CMV Disease. Excerpta Medica International Congress Series: Amsterdam, 1993, 1032: 233-237.
16. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
17. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
18. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19: 287-298.
19. Van der Bij W, Torensma R, Van Son JW et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25: 179-188.
20. Van der Bij W, Schirm J, Torensma R et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26: 2531-2535.
21. Boeckh M, Gallez-Hawkins GM, Myerson D et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation - comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113.
22. Jiwa NM, Van Gemert GW, Rapp AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leucocytes of viraemic transplant recipients by the polymerase chain reaction. Transplantation 1989; 48: 72-76.
23. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenaemia-guided treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 10: 4063-4071.
24. Craddock C, Szydlo R, Ward K et al. Impact of recipient CMV status on outcome after T-depleted volunteer unrelated donor (VUD) transplantation for CML. Br J Haematol 1998; 101 (Suppl.): 69.
25. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
26. Ippoliti C, Morgan A, Warkentin D et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997; 20: 491-495.
27. Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62: 376-380.
28. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 1992; 257: 238-241.
29. Gonczol E, Ianacone J, Ho W et al. Isolated gA/gB glyco-protein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers. Vaccine 1990; 8: 130-136.
30. + virus-specific CTL. J Med Virol 1994; 43: 103-110.